Obsessive-compulsive symptoms in major depressive disorder correlate with clinical severity and mixed features.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
23
2
2022
medline:
9
6
2022
entrez:
22
2
2022
Statut:
ppublish
Résumé
Obsessive-compulsive symptoms (OCS) are often reported in patients with bipolar disorder. The aim of this study was to investigate OCS and their related clinical features in major depressive disorder (MDD). The analysis involved 482 outpatients with MDD collected within the Combining Medications to Enhance Depression outcomes trial, who were assessed with scales for depression, suicidality, irritability, hypomanic symptomatology, and other comorbid psychiatric manifestations. OCS were reported in 27% of the sample. Patients with MDD experiencing OCS were found to differ from those not experiencing OCS by a greater severity of depression (d = 0.41, P = 0.0001), more hypomanic symptoms (d = 0.48, P < 0.0001) and mixed features (22% vs. 10%, P = 0.001), increased levels of suicidal thoughts (d = 0.40, P = 0.0001), a lower likelihood of achieving remission after antidepressant treatment (19% vs. 33%, P = 0.0109), as well as more comorbid anxiety disorders (i.e. panic disorder: d = 0.98, P < 0.0001; generalized anxiety disorder: d = 0.74, P < 0.0001; social phobia: d = 0.71, P < 0.0001), and post-traumatic stress disorder (d = 0.81, P < 0.0001). In light of these findings, clinicians should pay more attention to the occurrence of OCS in MDD, as these symptoms may reflect greater clinical severity, poorer treatment outcome, and increased risk for bipolarity.
Identifiants
pubmed: 35191860
doi: 10.1097/YIC.0000000000000396
pii: 00004850-202207000-00006
doi:
Substances chimiques
Antidepressive Agents
0
Banques de données
ClinicalTrials.gov
['NCT00590863']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
166-172Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Altman E (1998). Rating scales for mania: is self-rating reliable? J Affect Disord. 50:283–286.
Amerio A, Odone A, Liapis CC, Ghaemi SN (2014). Diagnostic validity of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review. Acta Psychiatr Scand. 129:343–358.
Amerio A (2019). Suicide risk in comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review. Indian J Psychol Med. 41:133–137.
Amrhein V, Greenland S, McShane B (2019). Scientists rise up against statistical significance. Nature. 567:305–307.
Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rössler W (2003). Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord. 73:133–146.
Baer L, Trivedi MH, Huz I, Rush AJ, Wisniewski SR, Fava M (2015). Prevalence and impact of obsessive-compulsive symptoms in depression: a STAR*D report. J Clin Psychiatry. 76:1668–1674.
Benazzi F (2009). Classifying mood disorders by age-at-onset instead of polarity. Prog Neuropsychopharmacol Biol Psychiatry. 33:86–93.
Chokka P, Ge H, Bougie J, Ettrup A, Clerzius G (2021). Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study. Ther Adv Psychopharmacol. 11:20451253211013148.
Ciuca A, Albu M, Perte A, Budau O, Miclea Ş, Miclea M (2011). The Romanian adaptation of the psychiatric diagnostic screening questionnaire (PDSQ). Cogn Brain Behav Interdiscip J. 15:69–93.
Corruble E, Legrand JM, Duret C, Charles G, Guelfi JD (1999). IDS-C and IDS-sr: psychometric properties in depressed in-patients. J Affect Disord. 56:95–101.
De Berardis D, Vellante F, Fornaro M, Orsolini L, Valchera A, Baroni G, et al. (2020). Rapid improvement of obsessive-compulsive disorder associated with schizophrenia with cariprazine add-on in a subject under paliperidone long-acting injection: a case report. Int Clin Psychopharmacol. 35:113–118.
Dold M, Bartova L, Souery D, Mendlewicz J, Serretti A, Porcelli S, et al. (2017a). Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. J Psychiatr Res. 91:1–13.
Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, et al. (2017b). The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes – results from a cross-sectional European multicenter study. Eur Neuropsychopharmacol. 27:625–632.
Dold M, Bartova L, Souery D, Mendlewicz J, Porcelli S, Serretti A, et al. (2018). Low comorbid obsessive-compulsive disorder in patients with major depressive disorder – findings from a European multicenter study. J Affect Disord. 227:254–259.
Domingues-Castro MS, Torresan RC, Shavitt RG, Fontenelle LF, Ferrão YA, Rosário MC, et al. (2019). Bipolar disorder comorbidity in patients with obsessive-compulsive disorder: prevalence and predictors. J Affect Disord. 256:324–330.
Fabbri C, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, et al. (2021). Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. J Affect Disord. 279:722–729.
Faul F, Erdfelder E, Lang AG, Buchner A (2007). G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 39:175–191.
Fineberg NA, Hollander E, Pallanti S, Walitza S, Grünblatt E, Dell’Osso BM, et al. (2020). Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. Int Clin Psychopharmacol. 35:173–193.
Hofmeijer-Sevink MK, Batelaan NM, van Megen HJGM, van den Hout MA, Penninx BW, van Balkom AJLM, et al. (2018). Presence and predictive value of obsessive-compulsive symptoms in anxiety and depressive disorders. Can J Psychiatry. 63:85–93.
Huz I, Nyer M, Dickson C, Farabaugh A, Alpert J, Fava M, et al. (2016). Obsessive-compulsive symptoms as a risk factor for suicidality in U.S. college students. J Adolesc Health. 58:481–484.
Koyuncu A, Tükel R, Ozyildirim I, Meteris H, Yazici O (2010). Impact of obsessive-compulsive disorder comorbidity on the sociodemographic and clinical features of patients with bipolar disorder. Compr Psychiatry. 51:293–297.
Krebs G, Mataix-Cols D, Rijsdijk F, Rück C, Lichtenstein P, Lundström S, et al. (2021). Concurrent and prospective associations of obsessive-compulsive symptoms with suicidality in young adults: a genetically-informative study. J Affect Disord. 281:422–430.
Krüger S, Cooke RG, Hasey GM, Jorna T, Persad E (1995). Comorbidity of obsessive compulsive disorder in bipolar disorder. J Affect Disord. 34:117–120.
Larun L, Helseth V, Bramness JG, Haugerud H, Høie B, Gråwe RW, et al. (2007). Dual diagnoses – substance use disorder and severe mental illness: part 1 – accuracy of screening and diagnostic instruments. Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH) (NIPH Systematic Reviews: Executive Summaries). http://www.ncbi.nlm.nih.gov/books/NBK464874/ . [Accessed 11 January 2022]
Mahasuar R, Janardhan Reddy YC, Math SB (2011). Obsessive-compulsive disorder with and without bipolar disorder. Psychiatry Clin Neurosci. 65:423–433.
Mazzarini L, Kotzalidis GD, Piacentino D, Rizzato S, Angst J, Azorin JM, et al.; BRIDGE-II-Mix Study Group (2018). Is recurrence in major depressive disorder related to bipolarity and mixed features? Results from the BRIDGE-II-Mix study. J Affect Disord. 229:164–170.
McIntyre RS, Soczynska JK, Cha DS, Woldeyohannes HO, Dale RS, Alsuwaidan MT, et al. (2015). The prevalence and illness characteristics of DSM-5-defined ‘mixed feature specifier’ in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord. 172:259–264.
Mucci F, Toni C, Favaretto E, Vannucchi G, Marazziti D, Perugi G (2018). Obsessive-compulsive disorder with comorbid bipolar disorders: clinical features and treatment implications. Curr Med Chem. 25:5722–5730.
Mundt JC, Marks IM, Shear MK, Greist JH (2002). The work and social adjustment scale: a simple measure of impairment in functioning. Br J Psychiatry. 180:461–464.
Olgiati P, Serretti A, Souery D, Dold M, Kasper S, Montgomery S, et al. (2018). Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. J Affect Disord. 227:777–786.
Olgiati P, Serretti A (2022). Post-traumatic stress disorder and childhood emotional abuse are markers of subthreshold bipolarity and worse treatment outcome in major depressive disorder. Int Clin Psychopharmacol. 37:1–8.
Orozco A, Cardoner N, Aragón CF, Ruiz-Murugarren S, Vicens M, Álvarez-Mon MÁ, et al. (2021). Obsessive-compulsive symptoms in anxiety and depressive disorders: influence of recent and/or traumatic life events. Rev Psiquiatr Salud Ment. 14:218–226.
Pallanti S, Grassi G, Cantisani A, Sarrecchia E, Pellegrini M (2011). Obsessive–compulsive disorder comorbidity: clinical assessment and therapeutic implications. Front Psychiatry. 2:70. https://www.frontiersin.org/article/10.3389/fpsyt.2011.00070 . [Accessed 2 February 2022]
doi: 10.3389/fpsyt.2011.00070
Pellegrini L, Maietti E, Rucci P, Casadei G, Maina G, Fineberg NA, et al. (2020). Suicide attempts and suicidal ideation in patients with obsessive-compulsive disorder: A systematic review and meta-analysis. J Affect Disord. 276:1001–1021.
Poyurovsky M, Braverman L, Weizman A (2021). Beneficial effect of quetiapine monotherapy in patients with bipolar depression and comorbid obsessive-compulsive disorder. Int Clin Psychopharmacol. 36:50–53.
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. (2003). The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 54:573–583.
Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, et al. (2011). Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 168:689–701.
Rush AJ, Zimmerman M, Wisniewski SR, Fava M, Hollon SD, Warden D, et al. (2005). Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord. 87:43–55.
Serretti A, De Ronchi D, Olgiati P (2021). Irritable mood and subthreshold hypomanic episodes correlate with more severe major depression. Neuropsychobiology. 80:425–436.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 59(Suppl 20):22–33;quiz 34.
Tondo L, Vázquez GH, Pinna M, Vaccotto PA, Baldessarini RJ (2018). Characteristics of depressive and bipolar disorder patients with mixed features. Acta Psychiatr Scand. 138:243–252.
Trivedi MH, Wisniewski SR, Morris DW, Fava M, Kurian BT, Gollan JK, et al. (2011a). Concise associated symptoms tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. J Clin Psychiatry. 72:765–774.
Trivedi MH, Wisniewski SR, Morris DW, Fava M, Gollan JK, Warden D, et al. (2011b). Concise health risk tracking scale: a brief self-report and clinician rating of suicidal risk. J Clin Psychiatry. 72:757–764.
Yang W, Zhang G, Jia Q, Qian Z-K, Yin G, Zhu X, et al. (2019). Prevalence and clinical profiles of comorbid anxiety in first episode and drug naïve patients with major depressive disorder. J Affect Disord. 257:200–206.
Yousefzadeh F, Sahebolzamani E, Sadri A, Mortezaei A, Aqamolaei A, Mortazavi SH, et al. (2020). 5-hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control. Int Clin Psychopharmacol. 35:254–262.
Zimmerman M, Chelminski I (2006). A scale to screen for DSM-IV Axis I disorders in psychiatric out-patients: performance of the Psychiatric Diagnostic Screening Questionnaire. Psychol Med. 36:1601–1611.
Zimmerman M, Mattia JI (1999). The reliability and validity of a screening Questionnaire for 13 DSM-IV Axis I disorders (the Psychiatric Diagnostic Screening Questionnaire) in psychiatric outpatients. J Clin Psychiatry. 60:677–683.